NEW YORK, June 7 (GenomeWeb News) - Underwriters of Alnylam Pharmaceuticals' initial public offering have exercised an over-allotment option, the company said today.


The underwriters have purchased an additional 750,000 shares of common stock at the IPO price of $6 per share, less an underwriting discount of $.42 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.